CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
凝集素在肿瘤免疫治疗工具与治疗靶点中的双重作用
英文原题：The dual role of lectins in cancer-immunotherapy tools and therapeutic targets.
查看英文原题
The dual role of lectins in cancer-immunotherapy tools and therapeutic targets.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
糖基化改变是癌症的标志之一，可塑造肿瘤微环境中的免疫识别。凝集素是结合聚糖的蛋白质，在这一过程中具有双重作用：既可识别肿瘤相关聚糖模式，也可被开发为治疗工具。本综述讨论利用凝集素进行癌症免疫治疗的新兴策略。工程化凝集素构建体，包括抗体-凝集素嵌合体、凝集素-药物偶联物和靶向聚糖的CAR-T 细胞，可识别肿瘤特异性糖基化特征。与此同时，内源性凝集素通路，如半乳糖凝集素-polyLacNAc轴和唾液酸-Siglec轴，可作为抑制抗肿瘤应答的糖基化免疫检查点，是有前景的治疗靶点。理解凝集素如何调节肿瘤-免疫相互作用，有助于开发整合抗原识别与聚糖感知的新一代免疫疗法。
展开英文摘要原文
Altered glycosylation is a hallmark of cancer that shapes immune recognition within the tumor microenvironment. Lectins-glycan-binding proteins-play a dual role in this process: they interpret tumor-associated glycan patterns and can also be exploited as therapeutic tools. In this review, we discuss emerging strategies that harness lectins in cancer immunotherapy. Engineered lectin-based constructs, including antibody-lectin chimeras, lectin-drug conjugates, and glycan-targeting CAR-T cells, enable recognition of tumor-specific glycosylation signatures.
At the same time, endogenous lectin pathways such as the galectin-polyLacNAc and sialic acid-Siglec axes function as glyco-immune checkpoints that suppress anti-tumor responses and represent promising therapeutic targets. Understanding how lectins regulate tumor-immune interactions may guide the development of next-generation immunotherapies integrating antigen recognition with glycan sensing.
论文信息
- 作者
- Dziewicka M、Graczyk-Jarzynka A
- 单位
- Department of Immunology, Mossakowski Medical Research Institute Polish Academy of Sciences, Warsaw, Poland.Poland
- 文献类型
- 综述
- 期刊
- FEBS letters2026 Jul 4
- 原文标识
- PubMed 42400321 · DOI 10.1002/1873-3468.70406